572.39
전일 마감가:
$560.93
열려 있는:
$574.37
하루 거래량:
461.05K
Relative Volume:
0.37
시가총액:
$60.76B
수익:
$14.09B
순이익/손실:
$4.50B
주가수익비율:
14.57
EPS:
39.28
순현금흐름:
$2.96B
1주 성능:
+4.46%
1개월 성능:
+11.81%
6개월 성능:
-17.60%
1년 성능:
-45.77%
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
2024-12-10 | 재개 | BofA Securities | Underperform |
2024-11-15 | 개시 | Wolfe Research | Outperform |
2024-11-14 | 개시 | Citigroup | Neutral |
2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2024-03-12 | 개시 | Bernstein | Outperform |
2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2023-11-09 | 개시 | Deutsche Bank | Hold |
2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
2023-08-21 | 재확인 | Oppenheimer | Perform |
2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
2022-06-06 | 개시 | Jefferies | Underperform |
2022-05-23 | 개시 | SVB Leerink | Outperform |
2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
2021-12-09 | 재개 | Wells Fargo | Overweight |
2021-12-07 | 재개 | Cowen | Market Perform |
2021-12-06 | 개시 | Goldman | Buy |
2021-11-19 | 재개 | BMO Capital Markets | Outperform |
2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
2021-06-29 | 개시 | H.C. Wainwright | Buy |
2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
2020-04-08 | 개시 | The Benchmark Company | Hold |
2020-03-31 | 개시 | Wolfe Research | Peer Perform |
2020-02-27 | 개시 | Barclays | Overweight |
2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
2020-02-11 | 업그레이드 | Argus | Hold → Buy |
2019-12-24 | 개시 | Raymond James | Mkt Perform |
2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2019-11-12 | 개시 | SunTrust | Hold |
2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
2019-10-17 | 재개 | BofA/Merrill | Neutral |
2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Acquired Rep. Robert Bresnahan, Jr. - MarketBeat
Regeneron Pharmaceuticals' (REGN) Buy Rating Reaffirmed at Canaccord Genuity Group - MarketBeat
ANI Pharma stock drops on trial setback (ANIP:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Legato Capital Management LLC - MarketBeat
Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances - Yahoo Finance
Balentine LLC Invests $680,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Morse Asset Management Inc Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Massachusetts Financial Services Co. MA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron's Trading Volume Surges 40.54% to $546 Million Ranking 212th in Stock Market - AInvest
Metastatic Castration-Resistant Prostate Cancer Clinical - openPR.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Victory Capital Management Inc. - MarketBeat
Metastatic Castration-Resistant Prostate Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Surface Oncology, Regeneron Pharmaceuticals - Barchart.com
Beacon Investment Advisory Services Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
M. Kulyk & Associates LLC Acquires 528 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lowered by Edgestream Partners L.P. - MarketBeat
Regeneron’s New Trial: A Game-Changer for Lung Cancer Treatment? - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Sells 21,337 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Y Intercept Hong Kong Ltd Has $6.16 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. Stock Analysis and ForecastExplosive trading growth - jammulinksnews.com
Los Angeles Capital Management LLC Has $4.93 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What drives Regeneron Pharmaceuticals Inc. stock priceOutstanding capital appreciation - jammulinksnews.com
Evergreen Wealth Management LLC Invests $3.59 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Neutralizing Antibody Market Surges with Monoclonal Therapy & - openPR.com
South Dakota Investment Council Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Private Advisor Group LLC Has $9.05 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What analysts say about Regeneron Pharmaceuticals Inc. stockSuperior trading gains - printweek.in
Is Regeneron Pharmaceuticals Inc. a good long term investmentHigh-yield growth strategies - jammulinksnews.com
678 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by AustralianSuper Pty Ltd - MarketBeat
Apollon Wealth Management LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish? - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Sumitomo Life Insurance Co. - MarketBeat
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. - The Motley Fool
Cwm LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron’s New Study on Anticoagulant Alternatives: A Potential Game Changer? - TipRanks
Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer? - TipRanks
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold? - The Globe and Mail
Bailard Inc. Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet? - 富途牛牛
Wealthfront Advisers LLC Sells 1,173 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Las bolsas europeas suben, con el foco en los resultados - Yahoo Finanzas
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리제네론 파마슈티컬스 주식 (REGN) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
McCourt Marion | EVP Commercial |
Nov 01 '24 |
Option Exercise |
381.40 |
1,000 |
381,400 |
13,931 |
McCourt Marion | EVP Commercial |
Nov 01 '24 |
Sale |
844.61 |
1,000 |
844,610 |
12,931 |
자본화:
|
볼륨(24시간):